SCHEMBL1946264

SCHEMBL1946264

O=c1[nH]cnc2c([C@@H](CO)NC(CO)CO)c[nH]c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PNP P00491 15/20 1.00
MTAP Q13126 1/20 0.51
HPRT1 P00492 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945120 1.00 PNP (1.00) PNPMTAPHPRT1
SCHEMBL1945118 1.00 PNP (1.00) PNPMTAPHPRT1
Hydrochloric Acid SCHEMBL1946550 0.99 PNP (0.97) PNPMTAPHPRT1
Hydrochloric Acid SCHEMBL1946553 0.99 PNP (0.97) PNPMTAPHPRT1
SCHEMBL1945760 0.90 PNP (0.82) PNPMTAPHPRT1
SCHEMBL1946798 0.78 PNP (0.64) PNPMTAP
SCHEMBL1946189 0.78 PNP (0.64) PNPMTAP
SCHEMBL1945322 0.78 PNP (0.64) PNPMTAP
SCHEMBL16152178 0.78 PNP (0.64) PNPMTAP
SCHEMBL1948863 0.77 PNP (0.63) PNPHPRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US claimed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US claimed
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2021-02-16 US disclosed
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2018-12-13 US disclosed
WO-2017062421-A1 USE OF MTAP INHIBITORS FOR THE TREATMENT OF LUNG DISEASE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-04-13 WO disclosed
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US disclosed
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US disclosed
EP-2395005-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases Industrial Research Limited (NZ) 2011-12-14 EP disclosed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US disclosed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US disclosed
WO-2008030119-A9 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2009-09-24 WO disclosed
WO-2008030119-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease MTAP, TYMP, TPMT PNP 5/4885MTAP 1/4885HPRT1 9/4885
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases PNP, TYMP, NTPCR PNP 1/4885MTAP 12/4885HPRT1 27/4885
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease MTAP, TYMP, TPMT PNP 5/4885MTAP 1/4885HPRT1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.